No I'm away since the 6th w limited internet access-as I stated on twitter before I left-guess you can take credit-btw-you're welcome to share my find of 2007 Halozyme presentation showing increase in Humira Bioavailability from 64% to 100% (amazing huh?) due to the addition of rhuph20. After all- we longs are all in this together.
Hey it's "Citizen" Pentech raising his failed argument yet again -yeah Baxter is so afraid of tigers that they are reporting better than expected uptake and conversion of HyQvia and are planning to expand it's indications-And as I wrote you before- with no response from you-I am making SO much money on my HALO long position-choosing to double down against all of the inane and just wrong positions you have taken here-you are a joke with a failed "Citizen Petition".
PH-20 has been shown to aid penetration of oncolytic virus through the tumor cell membrane- right now T-VEC only works for Malignant Melanoma into which the virus is injected. In order to treat internal organs, Amgen will need to break down-yes-the tumor cells membranes-enter HALO with PegpH20 along with new (ex AMGN) CFO and (ex AMGN) CEO and Director K Falberg - ex AMGN CFO. Bid Coming.
I don't want it either but the writing is on the wall -AMGN also has a CAR-T partnership with KITE - including solid tumors-how are they planning to make that happen? Kite doesn't even have switches-Pegph20 may be the answer.
It depends on how quickly they move- of course I think higher - big corporations move slowly and 202 may be halted on efficacy prior- will quickly send pps over 40 itself.
AMGN files 2 Petitions vs ABBV for Humira Biosimilar AP501-why won't they just Buyout HALO since it is well known that rhupH20 increases Humira bioavailbty by 56% (see 2007 paper presented by HALO at National meeting) - will work on biosimilars too.
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
- Co-Injection of rHuPH20 with Humira Estimated to Increase the Maximal Steady State Subcutaneous Bioavailability from 64% to 100% -
SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that final results of the Enhanze(TM) Technology clinical trial demonstrating improved absorption and bioavailability of a representative commercially-available large protein molecule therapeutic (LPMT) were presented at the 34th Annual Meeting of the Controlled Release Society in Long Beach, California. Enhanze Technology is Halozyme's enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20). The abstract describing this trial was rated by the Controlled Release Society as having notable high scientific quality and was designated for a podium presentation, which included a recently completed modeled population pharmacokinetic (PK) analysis used to estimate the effect of steady state co-administration of rHuPH20 with the LPMT.
An important corollary to this work is that it allows Polymorpho Nucleocytes- PMNs- to penetrate tumor- as was shown on Analyst day preclinical slide #35 -see SEC exhibit Jan 7 2015- SO PMNs like Activated T cells carry CD44- the HA binding receptor- SO if PegpH20 can carry out the penetration of PMNs into Pancreatic tumor cells- it just might do the same for CAR-T , TIL, and TCR- all carry CD44.
Pentech is a very consistent presence on this board- he's always wrong= like a rock.
Any Time- Excessive?- I'm as excited as you seem to be about our investment- I make the time to find out what I can and over the years I have been rewarded with some nice nuggets of info- did you see that 2007 paper I found from am obscure but national mtg where HALO presented their work w rhupH20 and Humira- increased biovalabilty over 50%. It went from 64% w/o rhu to 100% with it. When I find these things I feel like "Stout Cortez" seeing the Pacific for the first time.
Read the Paper and/or Look at the HALO Slide - around #35 in the Analyst Day Jan 7 2015 Presentation- PegpH20 is shown for the first time to facilitate CD44+ White Blood Cells- in this case Neutrophils' - cousins of Activated T cells (see CAR-T TIL TCR) - access INTO Pancreatic Cancer Cells. It is only a matter of time until a CAR-T, TCR, and or TIL maker puts 2 and 2 together and uses this data as a basis to make a deal with HALO to begin studying CD44+ Tcells and pegpH20 together. The mechanism of facilitation is the transformation by pegpH20 of immunosuppressive High Molecular weight HA into Immunostimulating Low Mol Wght HA. For more on this see my seeking alpha instablog- solid tumor CAR-T, pegpH20, and autoimmune defense.
Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Edwin R. Manuel1,*, Jeremy Chen1, Massimo D'Apuzzo2, Melanie G. Lampa1, Teodora I. Kaltcheva1, Curtis B. Thompson3, Thomas Ludwig4, Vincent Chung5, and Don J. Diamond1,*
+ Author Affiliations
Published OnlineFirst July 2015; doi: 10.1158/2326-6066.CIR-14-0214 Cancer Immunology Research
Bacterial-based therapies are emerging as effective cancer treatments and hold promise for refractory neoplasms, such as pancreatic ductal adenocarcinoma (PDAC), which has not shown significant improvement in therapy for more than 25 years. Using a novel combination of shIDO-ST, a Salmonella-based therapy targeting the immunosuppressive molecule indoleamine 2,3-dioxygenase (IDO), with an enzyme, PEGPH20, which depletes extracellular matrix hyaluronan, we observed extended survival with frequent total regression of autochthonous and orthotopic PDAC tumors. This observation was associated with migration and accumulation of activated polymorphonuclear neutrophils (PMN) from spleens into tumors, which was not seen using a scrambled control (shScr-ST). Purified splenic PMNs from PEGPH20/shIDO-ST-treated mice exhibited significant IDO knockdown and were able to kill tumor targets ex vivo through me
Titers Last Stand was the Citizens Petition to Block HyQvia- which is growing in distribution and indication for BAX_ Now Baxalta- The CEO commented that he has raised toe price premium because insurers' cost is still less for the entire infusion! Patients Love it! So there go your titers- Diabetes too expensive and NOT the focus of This CEO- that wa sFrosts's dream- he's at XON. Torley is exAMGN exONXX_ and will either make HALO into an Oncology Company or sell it to AMGN like ONXX- Based on a Future Blockbuster- PegpH20- HALO's Kyprolis- but wider scope and therefore BIgger.
I'm making So Much $ Betting Against your opinion on titers- you're putting up a straw man that has Nothing to do with PegpH20 and the many successful Enhanze programs- certainly Nothing to do with shIDO-ST- the canary in a coal mine for Solid Tumor CAR-T. Enjoy- I'm counting the $. Yes Brad was looking backward too- he ALSO said on SAME feed - which you left out- That I- me Fezz- not you Pentech- have Been Right on this stock. Bye.
Well Enhanze is also doing a great job funding PegpH20 trials - But Yes- The whole Immunotherapy story is Pegph20 transforming HMW HA to Low for CAR-T TCR & TIL.
Neutrophils enter the Pancreatic Tumor- going where no CAR-T has gone before- after PegpH20 turns Immunosuppressive High Molecular Weight HA into Immunopermissive LMW HA.
It's my pleasure- thanks for the kind words.
6 months- $40-50 12mos- Part of Amgen's Price Per Share- Most Likely but NOT by My Choice- I'd rather it be $60-75 and all ours.
I tried to post but YAHOO wouldn't list it all...
I believe the next major event is unscheduled- 1. Halt of 202 on efficacy with Rx of controls 2. Roche Ventanas submits Comp Diagnostic for FDA 30d review 3. ABBV announces Humira SC trials with Enhanze- don'tknow which is 1st-
MabTheraSC will probably be at ASH.